Selling, General, and Administrative Costs: AbbVie Inc. vs GSK plc

A Comparative Analysis of SG&A Expenses: AbbVie Inc. vs GSK plc

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of AbbVie Inc. and GSK plc from 2014 to 2023. Over this period, AbbVie Inc. saw a significant increase in SG&A expenses, peaking in 2022 with a 97% rise from its 2016 low. In contrast, GSK plc maintained a more stable trajectory, with expenses fluctuating modestly around the $10 billion mark. Notably, 2020 marked a pivotal year for both companies, with AbbVie Inc. experiencing a 62% surge in expenses, while GSK plc reached its highest expenditure. This financial insight highlights the strategic investments and operational shifts within these pharmaceutical giants, offering a window into their competitive strategies and market positioning.